A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Eligibility Criteria: * Male or female, between 18 and 65 years of age (female patients must be surgically sterile or 2 years post-menopausal and are required to take a pregnancy test) * Body Mass Index (BMI) 18 - 32 kg/m2 * Chronically infected with hepatitis C genotype-1 virus * Serum HCV RNA \> 5 log10 IU/mL * No previous treatment with interferon, peginterferon, ribavirin or any investigational HCV antiviral agents * No history of signs or symptoms of decompensated liver disease * No known history of cirrhosis * No co-infection with HBV, HIV-1, HIV-2 * No history of any medical condition that may interfere with absorption, distribution or elimination of study drug or with the clinical and laboratory assessments in this study * No history of alcohol abuse, or illicit drug use within 2 years prior to Screen, or enrollment in a methadone maintenance program (unless he/she has been enrolled in the methadone program for at least 3 months with good compliance, stable psychosocial circumstances, and no known current risks for recidivism)